GlassScriptPhysician profile
Bonnie Lo
NPI 1679063952
$962.84
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $25.88 · 2021: $276 · 2022: $97.78.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $238.90 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $136.71 | 2021 | |
| Amarin Pharma, INC. | $124.98 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $124.84 | 2021 | |
| Janssen Pharmaceuticals, INC | $119.35 | 2019 | |
| Alkermes, INC. | $97.78 | 2022 | |
| Novartis Pharmaceuticals Corporation | $40.23 | 2019-2021 | |
| Pfizer INC. | $39.33 | 2019 | |
| Mylan Specialty L.P. | $14.84 | 2019 | |
| Abbvie INC. | $13.77 | 2020 | |
| Corcept Therapeutics | $12.11 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bonnie Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.